Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Verastem, Inc. VSTM

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$30.9M
▲ 209.1% YoY
$-209.5M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We market AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) in the United States (“U.S.”), the first treatment specifically FDA-approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer (“LGSOC”) who have received prior systemic therapy. We are also conducting RAMP 301, a Phase 3 trial designed to evaluate avutometinib plus defactinib versus Investigator’s Choice of Treatment (“ICT”) in patients with recurrent LGSOC with and without a KRAS mutation. Our pipeline includes clinical-stage programs, preclinical research programs and externally partnered early-stage programs.

Written from the business description in Verastem, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 4 March 2026. Every sentence was checked against that document before publication.

Growth

USD 30.9M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 30.9 · Net income -209.5
40M80M-100M-200M
201120142017202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−678 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -550.3% · Net -677.6%
-1000%-2000%
201120182025
ROE
FY2023 · ROE -166.8%
-100%-200%
201120182025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -139%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -104.8
-50M-100M
201120182025

Total assetsUSD 246.4M
EquityUSD 57.2M
CashUSD 205.0M
Current ratio3.09×

Equity funds 23% of total assets.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
VSTM, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.0◌0.00.00.10.00.0◌◌◌◌◌◌◌
Operating income $B−0.2−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.2−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0
Income tax $B◌0.0◌0.00.00.00.00.0◌◌◌◌◌◌◌
Net income $B−0.2−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.0−0.0−0.0
Free cash flow $B◌−0.1◌◌−0.1−0.0−0.1−0.1◌−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−3.02−3.66−3.96−4.57−4.90−0.44−2.00−1.37−1.76−0.99−1.61−2.07−1.82−1.70−10.59
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %——−166.8−109.4−70.2−110.6−227.0−79.6−104.3−41.7−60.5−51.8−39.6——
Shares out B0.080.040.030.200.190.170.080.070.050.040.040.030.030.020.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 61 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. 11 checks were skipped: revenue is not tagged before 2018. Eight checks were skipped: the balance sheet is not tagged before 2011. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inMassachusetts
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image